Apimeds Pharma jumps as FDA backs faster approval path for non-opioid pain drugs

Shares of drug developer Apimeds Pharmaceuticals APUS.A rise 26.5% to $2.48 premarket

Late on Thursday, co welcomed new FDA draft guidance on non-opioid pain therapies

Co said the U.S. FDA's proposal could help move its lead non-opioid drug candidate, Apitox, more quickly through clinical trials and toward regulatory approval

Apitox is being developed to treat chronic pain caused by osteoarthritis, a condition that leads to long-term joint damage and reduced mobility

As of last close, stock down 11.8% YTD